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Under conventional heart failure therapy, inﬂammatory cardiomyopathy usually has a progressive course, merging for alternative
interventional strategies. There is accumulating support for the application of cellular transplantation as a strategy to
improve myocardial function. Mesenchymal stem cells (MSCs) have the advantage over other stem cells that they possess
immunomodulatory features, making them attractive candidates for the treatment of inﬂammatory cardiomyopathy. Studies in
experimental models of inﬂammatory cardiomyopathy have consistently demonstrated the potential of MSCs to reduce cardiac
injury and to improve cardiac function. This paper gives an overview about how inﬂammation triggers the functionality of MSCs
and how it induces cardiac homing. Finally, the potential of intravenous application of MSCs by inﬂammatory cardiomyopathy is
discussed.
1.Introduction
Myocarditis, described as an inﬂammatory inﬁltration of
the myocardium with necrosis and/or degeneration of car-
diomyocytes, is likely caused by a wide variety of infectious
organisms, autoimmune disorders, and exogenous agents
[1]. The major long-term consequence of myocarditis is
inﬂammatory dilated cardiomyopathy (DCMi) with chronic
heart failure. Persistent DCMi usually has a progressive
course under standard heart failure therapy. At present,
speciﬁc treatment options are not yet available or have not
yet been proofed in major trials. In virus-negative patients,
immunosuppression [2] is an option whereas in patients
with cardiac virus persistence, the role of immunoglobulin
or immunomodulation with interferon (IFN) [3]i su n d e r
investigation. Finally, immunoabsorption [4]c o u l db ea n
optioninfavouroftheideathatalsoautoantibodiesmayplay
a role in a subset of DCMi populations. However, the search
for alternative therapies is still open.
There is accumulating experimental [5, 6] and clinical
support [7–9] for the application of cellular transplantation
as a strategy to improve myocardial function. Mesenchymal
stem cells (MSCs) have antiapoptotic [10], antiﬁbrotic [11],
and proangiogenic [12] features. They have the advantage
over other stem cells that they have immunomodulatory
properties [13], which make them an attractive cell source
for the treatment of inﬂammatory cardiomyopathy, given
the importance of the inﬂammatory component in this
disorder. Application of MSCs in experimental models of
Coxsackievirus- (CVB-3) induced myocarditis [14]a n d
autoimmune myocarditis [5, 15], attenuated myocardial
injury and dysfunction. Both intramyocardial and intra-
venous administration of MSCs were successful. However,
the MSC-mediated reduction in cardiac injury in the acute
model of CVB3-induced myocarditis was not paralleled with
a decrease in cardiac viral load, disabling a view of the ﬁnal
outcome on the long term. Therefore, as long as evidence
in models of chronic virus-induced myocarditis are lacking,2 Cardiology Research and Practice
the use of MSCs could be more important or restricted for
the treatment of nonviral inﬂammatory cardiomyopathies.
Systemic delivery of MSCs requires eﬃcient homing of
MSCs to the place of injury. This review gives an overview
about how inﬂammation triggers the functionality of MSCs
and how it induces cardiac homing. The impact of inﬂam-
mation/cytokine expression on the diﬀerent aspects of hom-
ing, including chemokine-chemokine receptor interactions,
adhesion on endothelial cells, transendothelial migration,
and invasion through the extracellular matrix, is outlined.
Finally, the potential of intravenous application of MSCs by
inﬂammatory cardiomyopathy is discussed.
1.1. Mesenchymal Stem Cells. MSCs, which can be alterna-
tively referred to as multipotent mesenchymal stromal cells
or marrow stromal cells, are a heterogeneous population
of cells which can proliferate in vitro as plastic-adherent
cells, have ﬁbroblast-like morphology, form colonies in
vitro,a n dc a nd i ﬀerentiate into bone, cartilage, adipose,
and stromal tissues [16, 17]. MSCs are positive for many
characteristic markers including CD29, CD44, CD71, CD90,
CD106, CD120a, CD124, SH2, SH3, and SH4, and negative
for CD14, CD34, and CD45, which are speciﬁc markers
of hematopoietic stem cells [18]. MSCs are rare in bone
marrow, representing ∼1 in 10,000 nucleated cells.
MSCs have the capacity to diﬀerentiate into cardiomy-
ocytes, endothelial cells, and smooth muscle cells. Quevedo
et al. [6] could demonstrate via using female swine and
injecting male allogeneic MSCs 12 weeks after myocardial
infarction that engrafted MSCs diﬀerentiated into cardiomy-
ocytes as ascertained by colocalization with GATA-4, Nkx2.5,
and α-sarcomeric actin. In addition, Ypos MSCs exhibited
vascular smooth muscle and endothelial cell diﬀerentiation,
contributing to large and small vessel formation. Besides
their trilineage diﬀerentiation capacity [6], it is believed that
thecardioprotectiveeﬀectsofMSCarepredominantlydueto
facilitatingendogenousrepairprocessesviatheirantiﬁbrotic,
immunomodulatory, antiapoptotic and proangiogenic fea-
tures.
In brief, MSCs have the capacity to reduce cardiac
ﬁbroblast proliferation [19] and collagen I and III expression
[20], and they are able to promote matrix metalloproteinase
secretion by cardiac ﬁbroblasts [11], leading to reduced car-
diac ventricular ﬁbrosis. These eﬀects may at least partially
be mediated via the release of antiﬁbrotic factors such as
hepatocyte growth factor [21].
An emerging body of evidence indicates that MSCs
possess immunomodulatory properties, aﬀecting T cells
[13], dendritic cells [22], B cells [23], and natural killer cells
[24]. Immunosuppression occurs hereby most eﬀectively
under conditions in which MSCs make physical contact
with allogeneic tissue and release soluble factors, including
interleukin- (IL-)10, transforming growth factor- (TGF-)β,
Indoleamine 2,3-dioxygenase [25], and prostaglandin E2.
Moreover, the inﬂammatory environment/condition plays
an important role in the ability of MSCs to exert their
immunosuppressive eﬀects. In fact, in the absence of T
cell activation or exogenous inﬂammatory cytokines, MSCs
actually prolong the survival of lymphocytes [26], support-
ing the immunomodulatory nature of MSCs.
Studies in models of diabetic cardiomyopathy [10],
myocardial infarction [27], and myocarditis [14]d e m o n -
strated that MSC application leads to less cardiac apoptosis,
which might be in part due to improved angiogenesis
[27]. We demonstrated in vitro via coculture of MSCs
with CVB3-infected HL-1 cardiomyocytes that MSCs have
intrinsic antiapoptotic features, and that these eﬀects are
nitric oxide- (NO-)dependent [14]. Furthermore, Nagaya et
al. [5] showed that cultured MSCs secreted large amounts
of the angiogenic, antiapoptotic, and mitogenic factors
vascular endothelial growth factor, hepatocyte growth factor,
adrenomedullin, and insulin-like growth factor-1. Finally,
MSCs also have proangiogenic eﬀects: they can diﬀerentiate
into endothelial cells [28], increase in vitro tube formation
[12], and secrete proangiogenic factors including vascular
endothelial growth factor [29, 30]. Their proangiogenic
features have been demonstrated in models of peripheral
hindlimb ischemia [31] and myocardial infarction [27, 32].
1.2. Inﬂammatory Cytokines Induce Mesenchymal Stem Cell
Activation. Various reports have demonstrated the impor-
tance of IFN-γ for the activation of MSCs [13, 14, 33].
Sheng et al. [33] showed that IFN-γ, a well-known proin-
ﬂammatory cytokine produced by activated T cells, plays an
important role in priming the immunosuppressive property
of MSCs. Mechanistically, IFN-γ acts directly on MSCs
and leads to upregulation of B7-H1, an inhibitory surface
molecule in these stem cells. MSCs primed by activated T
cells derived from IFN-γ−/− mouse exhibited dramatically
reduced ability to suppress T cell proliferation, a defect that
could be rescued by supplying exogenous IFN-γ.M o r e o v e r ,
siRNA-mediated knockdown of B7-H1 in MSCs abolished
immunosuppression by these cells. In agreement Ren et
al. [13] found that the immunosuppressive function of
MSCs is elicited by IFN-γ and the concomitant presence
of any of three other proinﬂammatory cytokines, tumor
necrosis factor-α (TNF-α), IL-1α,o rI L - 1 β. These cytokine
combinations provoke the expression of high levels of
several chemokines and inducible nitric oxide synthase
(iNOS) by MSCs. Chemokines drive T cell migration into
the proximity of MSCs, where T cell responsiveness is
suppressed by NO. This cytokine-induced immunosuppres-
sion is absent in MSCs derived from iNOS−/− or IFN-
γR1−/− mice. Administration of wild-type MSCs, but not
of IFN-γR1−/− MSCs, prevented graft-versus-host disease in
mice, an eﬀect reversed by anti-IFN-γ or iNOS inhibitors.
Therefore,proinﬂammatorycytokinesarerequiredtoinduce
immunosuppression by MSCs through the concerted action
of chemokines and NO. Moreover, Ren et al. [34]f o u n d
thatintracellularadhesionmolecule-(ICAM-)1andvascular
cell adhesion molecule- (VCAM-)1 were critical for MSC-
mediatedimmunosuppression.WhenMSCswerecocultured
with T cells in the presence of T cell antigen receptor
activation, they signiﬁcantly upregulated the adhesive capa-
bility of T cells due to the increased expression of ICAM-
1 and VCAM-1. The greater the expression of ICAM-1 andCardiology Research and Practice 3
VCAM-1 by MSCs was, the greater the immunosuppressive
capacity that they exhibited. Furthermore, ICAM-1 and
VCAM-1 were found to be inducible by the concomitant
presence of IFN-γ and inﬂammatory cytokines (TNF-α,I L -
1). Finally, MSC-mediated immunosuppression was signif-
icantly reversed in vitro and in vivo when the adhesion
molecules were genetically deleted or functionally blocked,
which corroborated the importance of cell-cell contact in
immunosuppressionbyMSCs.Theseﬁndingsnotonlyreveal
anovelfunctionofadhesionmoleculesinimmunoregulation
byMSCs,butalsoprovidenewinsightsfortheclinicalstudies
of antiadhesion therapies in various immune disorders.
Furthermore, we demonstrated that MSCs not only
require IFN-γ to exert their immunomodulatory properties,
but also to perform their antiapoptotic, antioxidative, and
antiviral features [14]. Coculture of MSCs with Coxsack-
ievirus B3-infected HL-1 cardiomyocytes reduced cardiomy-
ocyte apoptosis, oxidative stress, and viral progeny release,
an eﬀect which was reduced in the presence of an IFN-γ
antibody [14]. In line with Oh et al. [35], we could also
demonstrate that MSCs request IFN-γ for the production of
NO, which is known for its antiapoptotic [36]a n da n t i v i r a l
properties [37].Furthermore,Kempetal.[38]demonstrated
that the secretion of the antioxidative enzyme superoxide
dismutase 3 by MSCs is regulated synergistically by TNF-α
and IFN-γ, rather than through direct exposure to reactive
oxygen species.
1.3. Cardiac Homing of Mesenchymal Stem Cells. Homing is
a multistep process which involves chemokine-chemokine
receptor interactions, adhesion to endothelial cells, trans-
migration through the endothelial vasculature, cytoskeleton
rearrangement, and adhesive interactions with the extracel-
lular matrix [39]. Numerous in vivo studies have shown that
MSCs have the capability to migrate from the blood, across
endothelial cells, into damaged tissues.
MSCsexpressavarietyofchemokines[40–42],including
CXCR4 and CCR2, the receptors for stromal cell-derived
factor- (SDF-)1α and monocyte chemoattractant protein-
(MCP-)1, respectively. SDF-1α is a CXC chemokine known
t op l a yac r i t i c a lr o l ei nt h et r a ﬃcking of hematopoietic cells
and stem cell progenitors and in maintaining hematopoietic
stem cellniches in bone marrow [43].SDF-1α expression has
been shown to increase under hypoxic conditions [44]a n d
thus may serve to attract stem cells to sites of tissue injury.
Its expression is signiﬁcantly upregulated in experimental
rat and mouse models of myocardial infarction [45–47],
in cardiac tissue of patients with myocardial ischemia
[48], and in experimental CVB3-induced myocarditis (own
unpublished data). Abbott et al. [47] could demonstrate
that administration of AMD3100, which speciﬁcally blocks
the binding of SDF-1α to its endogenous receptor CXCR4,
diminished bone marrow cells recruitment after myocardial
infarction, strongly suggesting a requirement for SDF-1α in
bone marrow cell recruitment to the infarcted heart. Forced
expressionofSDF-1αintheheartbyadenoviralgenedelivery
48 hours after myocardial infarction doubled bone marrow
cells recruitment over myocardial infarction. However, gene
transfer of SDF-1α did not enhance recruitment in the
absence of myocardial infarction, suggesting that SDF-1α
can augment, but is not singularly suﬃcient for bone
marrow cells recruitment to the heart. The importance
of the SDF-CXCR4 axis in cardiac homing of MSCs has
been demonstrated by CXCR-overexpressing MSCs showing
improved targeted cardiac migration and engraftment of
MSCs [49].
MCP-1 is upregulated upon myocardial infarction [50]
and is induced in experimental CVB3-induced myocarditis
[51], by which its cardiac expression correlates with the
inﬁltration of mononuclear cells in the heart. Though, the
importance of cardiac MCP-1 expression for the cardiac
homing of MSCs follows from a study of Belema-Bedada
et al. [52] which demonstrated that directed expression of
MCP-1inthemyocardiumledtospeciﬁchomingofMSCsto
theheart.Inaddition,theycouldshowthatMCP-1-mediated
MSCmigrationdependsonCCR2/FROUNTsignalinginthe
MSC, by which the adapter molecule FROUNT is required
for polarization, cytoskeletal reorganization, and clustering
of CCR2 on the cell surface of MSCs. Besides the induction
of cardiac chemokine expression, inﬂammation also triggers
the expression of chemokine receptors on the MSCs. Only
a small proportion of MSCs strongly expresses functionally
active CXCR4 receptor [53]. Shi et al. [54] demonstrated
that a cocktail of cytokines resulted in upregulation of
both cell surface and intracellular CXCR4, increasing in
vitro migration capacity to SDF-1α and homing to the
bone marrow of irradiated NOD/SCID mice. Croitoru-
Lamoury et al. [55] showed that TNF-α,I F N - γ,a n dI F N - β
inﬂuence the expression of chemokines and their receptors
in MSCs. This was further conﬁrmed by Ponte et al. [40]
demonstrating that TNF-α stimulation of MSCs increases
chemotaxis towards chemokines but not towards growth
factors.ThesedatasuggestthatthemobilizationofMSCsand
their subsequent homing to injured tissues may depend on
the systemic and local inﬂammatory state.
Numerous in vivo studies have shown that MSCs have
the capacity to migrate from the blood, across endothelial
cells into injured tissues. Many of the molecules, including
integrins, selectins, and chemokine receptors, known to be
involved in the tethering, rolling, adhesion, and transmigra-
tion of leukocytes from the bloodstream into tissues are also
expressed on MSCs. MSCs express the integrins α1, α2, α3,
α4, α5, αv, β1, β3, and β4, and approximately 50% of human
MSCs are thought to express the integrin very late antigen-
(VLA-)4 (α4β1, CD49d) [56] .T h ei m p o r t a n c eo fV L A - 4i n
the adherence of human MSCs to endothelial cells, under
shear ﬂow conditions, follows from the observation that the
use of a neutralizing antibody to this integrin decreased
MSC binding to endothelial cells. On the other hand, it
was observed that treating endothelial cells with a blocking
antibody to its counterpart adhesion molecule, VCAM-1,
induced a similar decrease in MSC adherence. Both ﬁndings
indicate the importance of the VLA-4/VCAM-1 axis for ﬁrm
MSC adherence to endothelial cells.
MSCs also express the adhesion molecules VCAM-1,
ICAM-1, ICAM-3, ALCAM, and endoglin/CD105 [57].
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cardiac microvascular endothelial cells and MSCs with TNF-
α or IL-1β before adhesion, increased the adhesion of
MSCs to endothelial cells under shear stress concentration
dependently. In agreement, in vivo,a c t i v a t i o no fM S C s
with TNF-α before injection signiﬁcantly enhanced cardiac
homing of MSCs. TNF-α-induced adhesion could be com-
pletely blocked by pretreating either cardiac microvascular
endothelial cells or MSCs with anti-VCAM-1 monoclonal
antibodies but not by anti-ICAM-1 antibodies. Therefore,
the adhesion of circulating MSCs in the heart appears to
be an endothelium-dependent process and to be sensitive to
modulation by activators of both MSCs and the endothe-
lium. Inﬂammation and the expression of VCAM-1 but
not of ICAM-1 on both MSCs and cardiac microvascular
endothelial cells appear to have a regulatory eﬀect on MSC
homing in the heart. Furthermore, R¨ uster et al. [56] showed
that MSCs display a coordinated rolling and adhesion
behavior on endothelial cells similar to peripheral blood
mononuclear cells for which they equally required P-selectin
andVCAM-1/VLA-4.Thisinvolvedrapidextensionofpodia,
rolling, and subsequent ﬁrm adhesion was increased when
endothelial cells were prestimulated with TNF-α.
A comparison between the cell adhesion molecule
expression proﬁle of the mobilized, circulating MSCs, and
tissue-derived MSCs may provide further insight into the
potential mechanisms of MSC homing.
The expression of chemokine receptors [49, 59]a n d
integrins [60, 61] on MSCs is not only beneﬁcial for cardiac
migration/adhesion, but also for MSC survival and cardiac
engraftment. However, the impact of inﬂammation on MSC
survival and cardiac engraftment is beyond the scope of this
review.
Uponadhesion,MSCsmigratethroughtheendothelium.
At present, little is known about the mechanism of MSC
transendothelial migration and which adhesion molecules
are involved. MSCs do not express PECAM-1/CD31, which
is required in leukocyte transmigration across the endothe-
lium. So, although the rolling and adhesion of MSCs on the
endothelium are similar to those of leukocytes, it seems that
MSCs use diﬀerent adhesion molecules for transendothelial
migration. Schmidt et al. [62] investigated the mechanism
of transendothelial migration in vitro using a coculture of
MSCs on an endothelial monolayer and analyzed direct
interactions. An increasing ﬂattened morphology of the
MSCs, starting 30 minutes upon coculture was followed
by total integration into the monolayer after 2 hours. In
vivo,usingisolatedheartperfusionswithgold-labelledMSCs
and electron microscopy, they detected that MSCs exhib-
ited direct cell-cell contacts. Tight junctions between the
endothelial cells became abolished resulting in a distinct split
betweenthecells.MSCsdevelopedtightcell-cellcontactsand
became integrated into the endothelial wall of the capillary
vessel. Finally, confocal laser scanning microscopy revealed
that 30 minutes of MSC perfusion was suﬃcient to observe
transmigration across the endothelium of approximately
30%ofthecells.Thispercentageroseto50%after60minutes
and remained nearly unchanged thereafter. This ﬁnding is
important in view of exposure times of MSCs in clinical
settings. Steingen et al. [63] demonstrated that the time
course of adhesion, integration, and transmigration depends
on the endothelial phenotype and is most eﬀective in venous
vessels of the myocardium. Furthermore, they showed that
transmigration not only requires the interaction of VCAM-
1 and VLA-4, as veriﬁed by blocking experiments, but also
triggers the clustering of beta1 integrins.
After transmigrating across the endothelium, MSCs
have to traﬃc through the extracellular matrix (ECM)
to ﬁrst inﬁltrate sites of tissue damage. MSCs strongly
express and synthesize matrix metalloproteinase 2 (MMP-2),
membrane type 1 MMP (MT1-MMP), tissue inhibitor of
metalloproteinase 1 (TIMP-1), and TIMP-2 [64]. In situ
zymographies infer the activation of gelatinases at sites of
MSC invasion into myocardial tissue [63]. The ability of
MSCstotraversereconstitutedhumanbasementmembranes
was eﬀectively blocked in the presence of synthetic MMP
inhibitors. Detailed studies by RNA interference revealed
that gene knock-down of MMP-2, MT1-MMP, or TIMP-2
substantially impaired MSC invasion whereas silencing of
TIMP-1 enhanced cell migration, indicating opposing roles
of both TIMPs in this process. Moreover, the inﬂammatory
cytokines TGF-β1, IL-1β,a n dT N F - α upregulated MMP-
2, MT1-MMP, and/or MMP-9 production in these cells,
resulting in a strong stimulation of chemotactic migration
through ECM whereas the chemokine SDF-1α exhibited
minor eﬀects on MMP/TIMP expression and cell invasion
[64].
In summary, the homing of MSCs to the heart in
inﬂammatory cardiomyopathy is triggered on diﬀerent levels
as outlined in Figure 1.
1.4. Route of Administration. Since MSCs have the capacity
to home to injured tissue, intravenous application may be
considered for inﬂammatory cardiomyopathy and might
even have advantages over intracoronary or transendocardial
application despite their reduced cardiac engraftment [65].
Indeed, via intravenous application, also the spleen could
be reached. The spleen is the reservoir of monocytes which
are recruited into the inﬂammatory heart via interaction
of the chemokine MCP-1, released by the heart, with its
cognate receptor CCR2, present on monocytes [51]. In case
of myocardial infarction, 40% to 70% of monocytes acutely
recruited to the infarct originate from a splenic reservoir
[66].Retrievedintheheart,cellsthenassumeacentralrolein
orchestrating the healing wound [67]. However, an excessive
inﬂammatory response is deleterious. As shown for myocar-
dial infarction where splenectomy or the arrested release
of monocytes from the splenic reservoir via angotensin-
converting enzyme inhibition reduced the recruitment into
the healing infarct and improved the myocardial infarction
outcome[68],ananti-inﬂammatoryimpactviaMSCsonthe
splenic monocyte reservoir in the context of inﬂammatory
cardiomyopathy could be further beneﬁcial in addition to
the direct MSC-mediated cardioprotective eﬀects, favoring
intravenous application.
In case of Coxsackievirus B3-induced inﬂammatory
cardiomyopathy, the ﬁltration of viral particles during acute
infection takes place in the spleen [69] and pre-B, B cells,Cardiology Research and Practice 5
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Figure 1: Proposed pathways how inﬂammation induces cardiac homing of mesenchymal stem cells. (a) TNF-α and/or Coxsackievirus B3
(CVB3) trigger the induction of cardiac expression of monocyte chemoattractant protein-1 (MCP-1) also known as CCL2. At the same
time, the expression of the corresponding chemokine receptor CCR2 is induced on mesenchymal stem cells (MSCs), stimulating cardiac
migration. (b) TNF-α induces vascular cellular adhesion molecule- (VCAM-)1 expression on the cardiac endothelium. The VLA-4/VCAM-1
axis is important for ﬁrm MSC adherence to endothelial cells. Next, MSCs transmigrate through the endothelium which also requires the
interaction of VCAM-1 and VLA-4. Finally, MSCs invade through the basement membrane and the extracellular matrix (ECM) via their
secretion of matrix metalloproteinase- (MMP-)2, MMP-9, and membrane type 1 MMP (MT1-MMP), which are upregulated by TNF-α.I n
the heart, MSCs can exert cardioprotective eﬀects, including their anti-inﬂammatory, antiﬁbrotic, and antiapoptotic features, among others,
via interleukin- (IL-)10 and nitric oxide (NO).
CD4+ helper T cells, and Mac-1+ macrophages are infected
[70]. Homing of MSCs to the spleen might inﬂuence the
condition of immune cells, including their activity [13],
apoptosis [71], as well as their viral infection [14, 70]
and potentially also their homing capacity [13]. The MSC-
mediated dissemination of infected immune cells in the
spleen might therefore reduce the inﬁltration of infected
immunecellsintheheartandconsequentlyleadtoadecrease
in cardiac damage.
Finally, the ease of application, as well as the ﬁnding
that MSCs transmigration is most eﬀective in venous vessels
of the myocardium [63], favor the intravenous route of
administration.
2. Conclusion andPerspectives
In conclusion, consistent evidence from in vitro and in vivo
experimental studies support a promoted cardiac homing6 Cardiology Research and Practice
of MSCs under inﬂammatory cardiomyopathy. This ﬁnding
together with the activation of MSCs via cytokines, and
the immunomodulatory properties of MSCs, make MSCs
an attractive cell source for the treatment of inﬂammatory
cardiomyopathy. The investigation of endogenous cardiac
homing in patients with inﬂammatory cardiomyopathy
versus control patients, currently ongoing in our working
group, is needed to conﬁrm these experimental ﬁndings
in a patient setting and will underscore the potential use
of intravenous application of MSCs for the treatment of
inﬂammatory cardiomyopathy. Finally, the importance of
adhesion molecules for cardiac homing of MSCs and the
immunosuppressive eﬀect of MSCs, position the use of
antiadhesion therapies for inﬂammatory cardiomyopathy in
perspective.
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